drugset / Trial / NCT06572111
A Study in Healthy Men to Test How BI 1839100 is Taken up and Handled by the Body
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This trial is conducted in healthy male subjects to evaluate the drug BI 1839100. The trial has two main parts. Part A aims to understand how BI 1839100 is processed in the body after an oral dose. It measures the total recovery of the drug and its radioactive label in urine and feces. It also determines the concentrations in blood plasma and investigates the drug's metabolic pathways. Part B aims to compare the absolute bioavailability of BI 1839100 when administered orally and intravenously.
Timeline
- Start
- 2024-09-30
- Primary completion
- 2024-10-28
- Completion
- 2025-09-02
Outcome
Outcome not reported
Stopped: “Company decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI 1839100 | Unknown | — | Oral |
Indications
No indication recorded.